文献速递浆细胞疾病造血干细胞移植与细胞治疗

AMG 701 诱导多发性骨髓瘤细胞毒性并清除食蟹猴浆细胞

AMG 701 induces cytotoxicity of multiple myeloma cells and depletes plasma cells in cynomolgus monkeys.
PubMed 文献 · Blood Adv · 2020-01-01

本研究评估半衰期延长的抗 BCMA BiTE 分子 AMG 701 的体外和体内活性。体外平均半数有效浓度为 18.8 ± 14.8 pM,小鼠模型中所有测试剂量均完全抑制肿瘤形成(P < .001)。食蟹猴中浆细胞特异性基因清除达血液 93%、骨髓 85%,支持临床开发。

要点

  • 小鼠模型中所有测试剂量完全抑制肿瘤形成(P < .001),并延长原位 MM 模型生存(P ≤ .01)。
  • 食蟹猴中浆细胞特异性基因清除达血液 93%、骨髓 85%。

核心结论

  • AMG 701 在体外和动物模型中显示抗多发性骨髓瘤活性并清除食蟹猴浆细胞,支持临床开发。

研究设计与样本

  • 体外细胞实验、皮下小鼠异种移植模型、原位 MM 模型及食蟹猴体内评估。
  • 食蟹猴中采用定量微滴式数字 PCR 检测浆细胞特异性基因,灵敏度为 0.1%。

主要发现

  • AMG 701 体外诱导针对表达 BCMA 的 MM 细胞的选择性细胞毒性,平均半数有效浓度为 18.8 ± 14.8 pM。
  • 皮下小鼠异种移植模型中所有测试剂量完全抑制肿瘤形成(P < .001)。
  • 小鼠模型中抑制已建立肿瘤生长(P ≤ .001)并延长原位 MM 模型生存(P ≤ .01)。
  • 食蟹猴中观察到剂量依赖性药代动力学和药效学行为,浆细胞特异性基因清除达血液 93%、骨髓 85%。
  • 体外与 PD-1 阻断抗体联用显著增加 AMG 701 效力。

关键数值与推荐

  • 体外平均半数有效浓度为 18.8 ± 14.8 pM。
  • 食蟹猴浆细胞特异性基因清除:血液 93%,骨髓 85%。
  • 数字 PCR assay 灵敏度为 0.1%。

临床怎么用

  • AMG 701 可作为靶向 BCMA 的 BiTE 分子用于多发性骨髓瘤的临床开发。
  • 与 PD-1 阻断抗体联用可能增强 AMG 701 的效力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Multiple myeloma (MM) is a hematologic malignancy that is characterized by the accumulation of abnormal plasma cells (PCs) in the bone marrow (BM). Patient outcome may be improved with BiTE (bispecific T-cell engager) molecules, which redirect T cells to lyse tumor cells. B-cell maturation antigen (BCMA) supports PC survival and is highly expressed on MM cells. A half-life extended anti-BCMA BiTE molecule (AMG 701) induced selective cytotoxicity against BCMA-expressing MM cells (average half-maximal effective concentration, 18.8 ± 14.8 pM), T-cell activation, and cytokine release in vitro. In a subcutaneous mouse xenograft model, at all doses tested, AMG 701 completely inhibited tumor formation (P < .001), as well as inhibited growth of established tumors (P ≤ .001) and extended survival in an orthotopic MM model (P ≤ .01). To evaluate AMG 701 bioactivity in cynomolgus monkeys, a PC surface phenotype and specific genes were defined to enable a quantitative digital droplet polymerase chain reaction assay (sensitivity, 0.1%). Dose-dependent pharmacokinetic and pharmacodynamic behavior was observed, with depletion of PC-specific genes reaching 93% in blood and 85% in BM. Combination with a programmed cell death protein 1 (PD-1)-blocking antibody significantly increased AMG 701 potency in vitro. A model of AMG 701 binding to BCMA and CD3 indicates that the distance between the T-cell and target cell membranes (ie, the immunological synapse) is similar to that of the major histocompatibility complex class I molecule binding to a T-cell receptor and suggests that the synapse would not be disrupted by the half-life extending Fc domain. These data support the clinical development of AMG 701.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Goldstein RL, Goyos A, Li CM, et al. AMG 701 induces cytotoxicity of multiple myeloma cells and depletes plasma cells in cynomolgus monkeys. Blood Adv. 2020. PMID: 32886754. doi:10.1182/bloodadvances.2020002565

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。